Abstract
Malignant pleural mesothelioma (MPM) is a malignant cancer originated from pleural mesothelial cell. The diagnosis of MPM is based on biopsy of pleura and immunohistochemistry. The current treatment of MPM is multimodality therapy including surgery, radiotherapy, chemotherapy and immunotherapy. There are two major surgical procedures: extrapleural pneumonectomy and pleurectomy/decortication. The main of radiotherapy is three-dimensional conformal radiotherapy. Cisplatinum combined with pemetrexed is the first-line chemotherapy for the patients with MPM. The principal targets for immunotherapy include regulatory T cells, cytotoxic T lymphocyte-associated antigen-4 and PD-1. Key words: Mesothelioma; Therapy; Immune system; Hematology
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
